Akoya Biosciences, Inc. (AKYA)
| Market Cap | 584.13M |
| Revenue (ttm) | 48.15M |
| Net Income (ttm) | n/a |
| Shares Out | 29.97M |
| EPS (ttm) | -2.94 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 76,889 |
| Open | 16.96 |
| Previous Close | 17.21 |
| Day's Range | 15.38 - 17.21 |
| 52-Week Range | 13.95 - 28.96 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | 26.00 (+65.4%) |
| Est. Earnings Date | Nov 9, 2021 |
About AKYA
Akoya Biosciences is an innovative life sciences technology company whose mission is to deliver a revolutionary new class of spatially derived biomarkers that empower life sciences researchers to better understand disease and clinicians to improve patient outcomes. Spatial biology refers to a rapidly evolving technology that enables academic and biopharma scientists to detect and map the distribution of cell types and biomarkers across whole tissue samples at single cell resolution, enabling advancements in their understanding of disease progre...
Financial Performance
In 2020, AKYA's revenue was $42.44 million, an increase of 0.49% compared to the previous year's $42.24 million. Losses were -$16.71 million, 13.3% more than in 2019.
Financial StatementsNews
Akoya Biosciences Appoints Diagnostics Industry Pioneer Myla Lai-Goldman, MD, to its Board of Directors
MARLBOROUGH, Mass., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ: AKYA) (“Akoya”), The Spatial Biology Company®, today announced the appointment of Myla Lai-Goldman, MD, a true pio...
Akoya Biosciences to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
MARLBOROUGH, Mass., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will be virtually participating in the Morga...
Akoya Reports 53% Revenue Growth in the Second Quarter of 2021
MARLBOROUGH, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the second quarter ending ...
Akoya Biosciences to Present at the Canaccord 41st Annual Growth Conference
MARLBOROUGH, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will be virtually participating in the Canac...
Akoya to Report Second Quarter 2021 Financial Results on August 10, 2021
MARLBOROUGH, Mass., July 20, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the secon...
Akoya Announces Publication of the MITRE Study, the First Multi-Institutional Analytical Demonstration of a Spatial B...
Results from the study provide evidence of standardization of an automated spatial biology workflow, based on the company's Phenoptics™ multiplex immunofluorescence (mIF) platform, for clinical and tran...
CrestOptics Selected by Akoya Biosciences for Spatial Biology Collaboration
ROME, Italy--(BUSINESS WIRE)--CrestOptics S.p.A., a manufacturer of high-end microscopy solutions and advanced systems for fluorescence microscopy and diagnostic applications, today announced that it ha...
Akoya to Partner with Nikon, CrestOptics and Andor to Enable New Spatial Biology Applications through the Imaging Inn...
Company plans to work with multiple microscope partners to broaden access to the CODEX® solution for single-cell, multiplexed imaging Company plans to work with multiple microscope partners to broaden a...
Akoya Biosciences Appoints Diagnostics Industry Leader Scott Mendel to its Board of Directors
MARLBOROUGH, Mass., June 25, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences Inc., (NASDAQ: AKYA), The Spatial Biology Company®, today announced the appointment of diagnostics industry leader Scott Mendel to...
Akoya to Help Support Leading Philanthropic Organization with Spatial Phenotyping Capabilities
CODEX's single-cell, multiplex imaging capabilities to be included in Chan Zuckerberg Initiative grantee toolkit to help fuel the next wave of biological discoveries CODEX's single-cell, multiplex imagi...
Akoya Announces Publication of New Immunotherapy Biomarker Signature in Science, Leveraging Principles of Astronomy a...
Investigators at Johns Hopkins University (JHU) used AstroPath to identify and validate biomarkers for accurate prediction of long-term response to immune checkpoint inhibitors in advanced melanoma
Akoya Set to Join Russell 3000® Index
MARLBOROUGH, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, is set to join the broad-market Russell 3000® Index at the conclusio...
Akoya and AstraZeneca to Collaborate on Spatial Biology Approach to Profiling Tumor-Immune Biology
Partnership aims to leverage spatial biology data, generated on Akoya's Phenoptics™ platform, to inform and guide drug development programs Partnership aims to leverage spatial biology data, generated o...
Akoya Announces Rollout of Strategic Clinical Research Program to Advance Adoption of Spatial Biology for Clinical Ap...
Company launches Advanced Biopharma Solutions (ABS), as the first pillar of the program, to enable spatial biomarker-guided drug development and clinical trials Company launches Advanced Biopharma Solut...
Akoya Reports First Quarter 2021 Financial Results and Issues Full Year 2021 Guidance
MARLBOROUGH, Mass., May 18, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the first quarter ending Ma...
Akoya and ZEISS to Co-Market Innovative CODEX® Spatial Biology Workflow
The partnership brings together one of the world's premier microscopy vendors and Akoya's high-parameter CODEX® System for advancing the emerging field of spatial phenotyping and discovery The partnersh...
Akoya to Report First Quarter 2021 Financial Results on May 18, 2021
MARLBOROUGH, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the first ...
Akoya Biosciences Begins Accepting Applications for First-of-its-Kind Imaging Innovators (I²) Network
Seeking researchers interested in pushing the boundaries of spatial biology and discovery through the CODEX® system's open, accessible interface Seeking researchers interested in pushing the boundaries ...
DLA Piper advises Akoya Biosciences in its US$151 million initial public offering
NEW YORK, May 3, 2021 /PRNewswire/ -- DLA Piper represented Akoya Biosciences, Inc. (Nasdaq: AKYA) in its recent initial public offering of 7,567,000 shares of its common stock at a price of $20 per sha...
Akoya Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Addition...
MARLBOROUGH, Mass., April 20, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced the closing of its initial public offering of 7,567...
Akoya Biosciences Announces Pricing of Initial Public Offering
MARLBOROUGH, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced the pricing of its initial public offering of 6,580...
Akoya Biosciences IPO Registration Document (S-1)
Akoya Biosciences, Inc. has filed to go public with an IPO on the NASDAQ.